Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SCNI with free AI briefings, catalyst countdowns, and dilution alerts.

SCNI · Scinai Immunotherapeutics Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$14.8M Cash, Pro Forma
21.3mo Cash Runway
Follow SCNI by email Get an email when SCNI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCNI, unsubscribe in one click. Privacy

📣 What SCNI Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

SCNI had $10.8M in cash and short-term investments on its Mar 31, 2023 balance sheet. Including the cash events since then, it holds about $14.8M pro forma, before operating spending after that date:

It burns about $2.1M/quarter from operations, an estimated runway of 21.3 months from Mar 31, 2023 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCNI files for a raise →

👥 Who Owns SCNI

Insiders 7.4% Institutions (11 holders) 0.6% Public and other holders 92%
HolderTypeShares% of sharesAs of
Amir Reichman
Chief Executive Officer, Director
Insider 711,637,600 5.13% 2026-06-16
Elad Mark
Chief Operating Officer
Insider 160,355,016 1.16% 2026-03-18
Mark Germain
Director
Insider 120,000,000 0.86% 2026-06-16
Uri Ben-Or
Director
Insider 33,329,004 0.24% 2026-03-18
LCK JNK 1 LLC 5%+ holder (13G) 317,366 0.00% 2026-04-27

Share count 13,872,899,584 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SCNI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCNI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.